Evidence map›Paper›PMID 40002899›Full record

ArticleBiomedicines2025

Notch1 siRNA and AMD3100 Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease.

Chunli Zhu, Yiheng Cheng, Lei Yang, Yifu Lyu, Jingjing Li, Pengbo Zhao, Ying Zhu, Xiaofei Xin, Lifang Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunli ZhuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Yiheng ChengDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Lei YangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0001-5107-2416
Yifu LyuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Jingjing LiDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Pengbo ZhaoDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Ying ZhuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Xiaofei XinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0002-7618-0808
Lifang YinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.

Funding

National Center of Technology Innovation for Biopharmaceuticals NCTIB2022HS01015National Natural Science Foundation of China 82304410National Natural Science Foundation of China 82473864Natural Science Foundation of Jiangsu Province BK20221045
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cellular crosstalkfibrosis and inflammationmacrophage phenotype switchingMASLDsiNotch1 and AMD3100

Identifiers

PMID40002899
PMCPMC11853639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.